Efficacy and safety of switching from branded to generic antiretrovirals in virologically suppressed HIV-infected patients.

Nicola GianottiAndrea PoliLaura GalliMichela FranzinPatrizia TadiniNadia GalizziAlessia CarboneMarco MerliCamilla MucciniChiara OltoliniAndrea AndolinaVincenzo SpagnuoloAdriano LazzarinAntonella Castagna

Published in: PloS one (2017)

After more than one year of follow-up, we found no evidence of increased risk of reduced efficacy or increased toxicity after switching from branded to generic lamivudine or zidovudine/lamivudine or efavirenz.

Keyphrases

hiv infected patients
antiretroviral therapy
hiv infected